Schmitz-Dräger BJ - Search Results

1

Considerations on the use of urine markers in the management of patients with high-grade non-muscle-invasive bladder cancer.

Kamat AM, Vlahou A, Taylor JA, Hudson ML, Pesch B, Ingersoll MA, Todenhöfer T, van Rhijn B, Kassouf W, Barton Grossman H, Behrens T, Chandra A, Goebell PJ, Palou J, Sanchez-Carbayo M, Schmitz-Dräger BJ. Kamat AM, et al. Urol Oncol. 2014 Oct;32(7):1069-77. doi: 10.1016/j.urolonc.2014.06.017. Epub 2014 Oct 11. Urol Oncol. 2014. PMID: 25306288 Review.

2

P53 accumulation in precursor lesions and early stages of bladder cancer.

Schmitz-Dräger BJ, van Roeyen CR, Grimm MO, Gerharz CD, Decken K, Schulz WA, Bültel H, Makri D, Ebert T, Ackermann R. Schmitz-Dräger BJ, et al. World J Urol. 1994;12(2):79-83. doi: 10.1007/BF00184241. World J Urol. 1994. PMID: 8087143

3

[Immunotherapy of superficial bladder cancer].

Schmitz-Dräger BJ, Schattka SO, Ebert T. Schmitz-Dräger BJ, et al. Urologe A. 1993 Sep;32(5):374-81. Urologe A. 1993. PMID: 8212422 Review. German.

4

p53 and MDM2 in the development and progression of bladder cancer.

Schmitz-Dräger BJ, Kushima M, Goebell P, Jax TW, Gerharz CD, Bültel H, Schulz WA, Ebert T, Ackermann R. Schmitz-Dräger BJ, et al. Eur Urol. 1997;32(4):487-93. Eur Urol. 1997. PMID: 9412812

5

p53 immunohistochemistry as a prognostic marker in bladder cancer. Playground for urology scientists?

Schmitz-Dräger BJ, Goebell PJ, Ebert T, Fradet Y. Schmitz-Dräger BJ, et al. Eur Urol. 2000 Dec;38(6):691-9;discussion 700. doi: 10.1159/000020364. Eur Urol. 2000. PMID: 11111186

6

Use of markers in defining urothelial premalignant and malignant conditions.

Grossman HB, Schmitz-Dräger B, Fradet Y, Tribukait B. Grossman HB, et al. Scand J Urol Nephrol Suppl. 2000;(205):94-104. doi: 10.1080/003655900750169347. Scand J Urol Nephrol Suppl. 2000. PMID: 11144908 Review.

7

p21 and p53 Immunostaining and survival following systemic chemotherapy for urothelial cancer.

Jankevicius F, Goebell P, Kushima M, Schulz WA, Ackermann R, Schmitz-Dräger BJ. Jankevicius F, et al. Urol Int. 2002;69(3):174-80. doi: 10.1159/000063949. Urol Int. 2002. PMID: 12372883

8

The International Bladder Cancer Bank: proposal for a new study concept.

Goebell PJ, Groshen S, Schmitz-Dräger BJ, Sylvester R, Kogevinas M, Malats N, Sauter G, Barton Grossman H, Waldman F, Cote RJ. Goebell PJ, et al. Urol Oncol. 2004 Jul-Aug;22(4):277-84. doi: 10.1016/S1078-1439(03)00175-3. Urol Oncol. 2004. PMID: 15283883

9

Concepts for banking tissue in urologic oncology--the International Bladder Cancer Bank.

Goebell PJ, Groshen S, Schmitz-Dräger BJ, Sylvester R, Kogevinas M, Malats N, Sauter G, Grossman HB, Dinney CP, Waldman F, Cote RJ. Goebell PJ, et al. Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):413-5. Clin Cancer Res. 2005. PMID: 15701822 Review. No abstract available.

10

Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers.

Lokeshwar VB, Habuchi T, Grossman HB, Murphy WM, Hautmann SH, Hemstreet GP 3rd, Bono AV, Getzenberg RH, Goebell P, Schmitz-Dräger BJ, Schalken JA, Fradet Y, Marberger M, Messing E, Droller MJ. Lokeshwar VB, et al. Urology. 2005 Dec;66(6 Suppl 1):35-63. doi: 10.1016/j.urology.2005.08.064. Urology. 2005. PMID: 16399415

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

138 results

Search Page